Physician profile
Gilbert Teixeira
NPI 1194702530
$2,972.59
in general payments reported to CMS, 2019-2025
32 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,097 · 2020: $445 · 2023: $14.25 · 2024: $175 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $433.57 | 2019-2020 | |
| Amgen INC. | $338.66 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $280.44 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $270.28 | 2019-2020 | |
| Novo Nordisk INC | $255.93 | 2019-2020 | |
| Amarin Pharma, INC. | $137.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.37 | 2019-2020 | |
| Sonex Health, INC. | $131.94 | 2025 | Sx-One Microknife |
| Astellas Pharma US INC | $120.00 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $117.80 | 2019 | |
| Indivior INC. | $110.15 | 2019-2020 | |
| Allergan, INC. | $90.99 | 2019-2020 | |
| Lilly USA, LLC | $88.45 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $57.88 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.87 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $37.03 | 2019 | |
| Gilead Sciences, INC. | $28.32 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.95 | 2019 | |
| Sunovion Pharmaceuticals INC. | $26.13 | 2019 | |
| Abbott Laboratories | $24.18 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $23.29 | 2019 | |
| Shire North American Group INC | $23.18 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.09 | 2024 | |
| Viiv Healthcare Company | $23.07 | 2024 | Apretude |
| Exact Sciences Corporation | $21.33 | 2025 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $20.18 | 2019 | |
| Glaxosmithkline, LLC. | $15.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.12 | 2019 | |
| Kaleo, INC. | $14.76 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.49 | 2019 | |
| Philips North America LLC | $12.47 | 2019 | |
| Orexo US, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Teixeira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.